Pioneering A Novel Medicine For Fibrosis

We are developing a novel medicine to prevent, heal, and slow organ scarring due to fibrotic disease.

Read more about us

AM1476 granted Orphan Drug Designation in the US and EU for treatment of Systemic Sclerosis

See press release

AM1476 is our highly selective, peripheral-acting 5‑HT2B receptor antagonist

Read more

AM1476 offers a unique dual-action potential to treat both skin and lung manifestations of systemic sclerosis

Read more

AM1476 is Phase II ready, supported by Phase I and preclinical proof-of-concept studies

Read more